A Case Report of Lipoma-Like Hibernoma in Axilla: a Rarely Benign Tumor of Brown Adipose Tissue
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Who, How and What of Pathology of Soft Tissue Sarcoma
Editorial Page 1 of 11 Who, how and what of pathology of soft tissue sarcoma Salvatore Lorenzo Renne Anatomic Pathology Unit, Humanitas Research Hospital, Humanitas University, Rozzano, MI 20089, Italy Correspondence to: Salvatore Lorenzo Renne. Adjunct Teaching Professor, Anatomic Pathology Unit, Humanitas Research Hospital, Humanitas University, Via Manzoni 56, Rozzano, MI 20089, Italy. Email: [email protected]. Submitted Aug 06, 2018. Accepted for publication Aug 23, 2018. doi: 10.21037/cco.2018.10.09 View this article at: http://dx.doi.org/10.21037/cco.2018.10.09 Introduction to soft tissue sarcoma (STS) adipocytes (lipoma, spindle cells lipoma, hibernoma, well- pathology differentiated liposarcoma (LPS), myxoid LPS, etc.). One chapter is dedicated to specific entities “of uncertain STS is a generic term that refers to a heterogeneous group differentiation” that are well-characterized entities that do of rare neoplastic diseases. The aim of this review is to not readily resemble any normal mesenchymal cells (as the discuss the role of pathology in the multidisciplinary Ewing sarcoma or the synovial sarcoma—a clear misnomer). management of STS patients. This will be done: (I) The last chapter is dedicated to those sarcomas that do illustrating the framework for the current classification; (II) not follow in any of the previously listed diagnosis and are examining the characteristics that allows an expert diagnosis; therefore called “undifferentiated/unclassified sarcomas” (III) describing the role of the sarcoma pathologist -
Complete Case of a Rare but Benign Soft Tissue Tumor
Hindawi Case Reports in Orthopedics Volume 2019, Article ID 6840693, 5 pages https://doi.org/10.1155/2019/6840693 Case Report Hibernoma of the Upper Extremity: Complete Case of a Rare but Benign Soft Tissue Tumor Thomas Reichel ,1 Kilian Rueckl,1 Annabel Fenwick,1,2 Niklas Vogt,3 Maximilian Rudert,1 and Piet Plumhoff1 1Department of Orthopedic Surgery, Koenig-Ludwig-Haus, University of Wuerzburg, Brettreichstraße 11, 97074 Wuerzburg, Germany 2Department of Trauma Surgery, Klinikum Augsburg, 86156 Augsburg, Germany 3Department of Pathology, University of Wuerzburg, 97080 Wuerzburg, Germany Correspondence should be addressed to Thomas Reichel; [email protected] Received 26 February 2019; Accepted 14 April 2019; Published 21 May 2019 Academic Editor: Elke R. Ahlmann Copyright © 2019 Thomas Reichel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hibernoma is a rare benign lipomatous tumor showing differentiation of brown fatty tissue. To the author’s best knowledge, there is no known case of malignant transformation or metastasis. Due to their slow, noninfiltrating growth hibernomas are often an incidental finding in the third or fourth decade of life. The vast majority are located in the thigh, neck, and periscapular region. A diagnostic workup includes ultrasound and contrast-enhanced MRI. Differential diagnosis is benign lipoma, well- differentiated liposarcoma, and rhabdomyoma. An incisional biopsy followed by marginal resection of the tumor is the standard of care, and recurrence after complete resection is not reported. The current paper presents diagnostic and intraoperative findings of a hibernoma of the upper arm and reviews similar reports in the current literature. -
The Use of High Tumescent Power Assisted Liposuction in the Treatment of Madelung’S Collar
Letter to the Editor The use of high tumescent power assisted liposuction in the treatment of Madelung’s collar Henryk Witmanowski1,2, Łukasz Banasiak1, Grzegorz Kierzynka1, Jarosław Markowicz1, Jerzy Kolasiński1, Katarzyna Błochowiak3, Paweł Szychta1,4 1Department of Plastic, Reconstructive and Aesthetic Surgery, Medical College in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland 2Department of Physiology, Poznan University of Medical Sciences, Poznan, Poland 3Department of the Oral Surgery, Poznan University of Medical Sciences, Poznan, Poland 4Department of Oncological Surgery and Breast Diseases, Polish Mother’s Memorial Hospital-Research Institute, Lodz, Poland Adv Dermatol Allergol 2017; XXXIV (4): 366–371 DOI: https://doi.org/10.5114/ada.2017.69319 Mild symmetrical lipomatosis (plural symmetrical The disease most commonly takes a proximal form lipomatosis, multiple symmetric lipomatosis – MSL), which takes the following areas of the body with the fol- also known as Madelung’s disease or Launois-Bensaude lowing frequency: the genial area 92.3%, cervical region syndrome is a rare disease of unknown etiology, first de- 67.7%, shoulder region 54.8%, abdominal 45.2%, chest scribed by Brodie in 1846, Madelung in 1888, and Launois 41.9%, thigh and pelvic rim 32.3% [11, 12]. The periph- with Bensaude in 1898 [1–3]. eral type mainly locates on both sides at the level of the Madelung’s disease incidence is 1 : 250000 [4]. Mul- hands, feet and knees, this is definitely a rarer form of tiple symmetric lipomatosis occurs mainly in the inhabit- the disease. The mixed form is described very rarely. The ants of the Mediterranean area and Eastern Europe, in specified central type is also engaged primarily around males (male to female ratio is 20 : 1), aged 30–70 years, the lower torso, and intermediate parts of the legs. -
Appendix 4 WHO Classification of Soft Tissue Tumours17
S3.02 The histological type and subtype of the tumour must be documented wherever possible. CS3.02a Accepting the limitations of sampling and with the use of diagnostic common sense, tumour type should be assigned according to the WHO system 17, wherever possible. (See Appendix 4 for full list). CS3.02b If precise tumour typing is not possible, generic descriptions to describe the tumour may be useful (eg myxoid, pleomorphic, spindle cell, round cell etc), together with the growth pattern (eg fascicular, sheet-like, storiform etc). (See G3.01). CS3.02c If the reporting pathologist is unfamiliar or lacks confidence with the myriad possible diagnoses, then at this point a decision to send the case away without delay for an expert opinion would be the most sensible option. Referral to the pathologist at the nearest Regional Sarcoma Service would be appropriate in the first instance. Further International Pathology Review may then be obtained by the treating Regional Sarcoma Multidisciplinary Team if required. Adequate review will require submission of full clinical and imaging information as well as histological sections and paraffin block material. Appendix 4 WHO classification of soft tissue tumours17 ADIPOCYTIC TUMOURS Benign Lipoma 8850/0* Lipomatosis 8850/0 Lipomatosis of nerve 8850/0 Lipoblastoma / Lipoblastomatosis 8881/0 Angiolipoma 8861/0 Myolipoma 8890/0 Chondroid lipoma 8862/0 Extrarenal angiomyolipoma 8860/0 Extra-adrenal myelolipoma 8870/0 Spindle cell/ 8857/0 Pleomorphic lipoma 8854/0 Hibernoma 8880/0 Intermediate (locally -
The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft-Tissue Tumors Julia a Bridge
Modern Pathology (2014) 27, S80–S97 S80 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors Julia A Bridge Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA Soft-tissue sarcomas are rare, comprising o1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with 4100 benign and malignant soft-tissue tumor entities defined. Not infrequently, these neoplasms exhibit overlapping clinicopathologic features posing significant challenges in rendering a definitive diagnosis and optimal therapy. Advances in cytogenetic and molecular science have led to the discovery of genetic events in soft- tissue tumors that have not only enriched our understanding of the underlying biology of these neoplasms but have also proven to be powerful diagnostic adjuncts and/or indicators of molecular targeted therapy. In particular, many soft-tissue tumors are characterized by recurrent chromosomal rearrangements that produce specific gene fusions. For pathologists, identification of these fusions as well as other characteristic mutational alterations aids in precise subclassification. This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them. Emphasis is placed on the role of molecular pathology in the management of soft-tissue tumors. Familiarity with these genetic events -
Pathology and Genetics of Tumours of Soft Tissue and Bone
bb5_1.qxd 13.9.2006 14:05 Page 3 World Health Organization Classification of Tumours WHO OMS International Agency for Research on Cancer (IARC) Pathology and Genetics of Tumours of Soft Tissue and Bone Edited by Christopher D.M. Fletcher K. Krishnan Unni Fredrik Mertens IARCPress Lyon, 2002 bb5_1.qxd 13.9.2006 14:05 Page 4 World Health Organization Classification of Tumours Series Editors Paul Kleihues, M.D. Leslie H. Sobin, M.D. Pathology and Genetics of Tumours of Soft Tissue and Bone Editors Christopher D.M. Fletcher, M.D. K. Krishnan Unni, M.D. Fredrik Mertens, M.D. Coordinating Editor Wojciech Biernat, M.D. Layout Lauren A. Hunter Illustrations Lauren A. Hunter Georges Mollon Printed by LIPS 69009 Lyon, France Publisher IARCPress International Agency for Research on Cancer (IARC) 69008 Lyon, France bb5_1.qxd 13.9.2006 14:05 Page 5 This volume was produced in collaboration with the International Academy of Pathology (IAP) The WHO Classification of Tumours of Soft Tissue and Bone presented in this book reflects the views of a Working Group that convened for an Editorial and Consensus Conference in Lyon, France, April 24-28, 2002. Members of the Working Group are indicated in the List of Contributors on page 369. bb5_1.qxd 22.9.2006 9:03 Page 6 Published by IARC Press, International Agency for Research on Cancer, 150 cours Albert Thomas, F-69008 Lyon, France © International Agency for Research on Cancer, 2002, reprinted 2006 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. -
Treatment Strategies for Well-Differentiated Liposarcomas and Therapeutic Outcomes
ANTICANCER RESEARCH 32: 1821-1826 (2012) Treatment Strategies for Well-differentiated Liposarcomas and Therapeutic Outcomes NORIO YAMAMOTO1, KATSUHIRO HAYASHI1, YOSHIKAZU TANZAWA1, HIROAKI KIMURA1, AKIHIKO TAKEUCHI1, KENTARO IGARASHI1, HIROYUKI INATANI1, SHINGO SHIMOZAKI1, SEIKO KITAMURA2 and HIROYUKI TSUCHIYA1 1Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan; 2Department of Pathology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan Abstract. This study examined 45 patients with well- liposarcoma tends to be less than the one performed in differentiated liposarcoma who were surgically treated at our conventional extensive resection (7, 8). However, operative hospital (initial surgery in 41 patients and reoperation in 4). procedures from marginal resection to extensive resection Only one patient had recurrence among patients who vary among institutions. In this study, we examined the underwent initial surgery, and the recurrence was localised outcomes of well-differentiated liposarcomas treated at our in the retroperitoneal space. For patients who underwent hospital and we discuss future treatment strategies. reoperation, the mean time between the initial surgery and the recurrence was 16.5 years. None of the 45 patients Patients and Methods developed distant metastasis. It is important to preserve not only neurovascular bundles but also lower limb muscles in The subjects of this study were 45 patients with well-differentiated order to maintain ambulatory ability in the elderly patients. liposarcomas who were surgically treated in our hospital between For well-differentiated liposarcomas of the limbs, it is January 1989 and July 2010 and who were followed-up for at least 6 months. The study group consisted of 17 men and 28 women. -
Lipoblastoma: a Rare Soft Palate Mass
International Journal of Pediatric Otorhinolaryngology Extra 5 (2010) 134–137 Contents lists available at ScienceDirect International Journal of Pediatric Otorhinolaryngology Extra journal homepage: www.elsevier.com/locate/ijporl Case report Lipoblastoma: A rare soft palate mass Myriam Loyo a, Alejandro Rivas a, David Brown b,* a Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, United States b Division of Pediatric Otolaryngology, Department of Otolaryngology & Communication Sciences, Medical College of Wisconsin, Milwaukee, WI, United States ARTICLE INFO ABSTRACT Article history: Lipoblastomas are rare benign tumors originating from embryonic fat cells that continue to proliferate in Received 26 May 2009 the postnatal period. Most tumors occur around age three and are found predominantly in the Received in revised form 18 July 2009 extremities and trunk. Less than fifteen cases have been reported in the head and neck region. We Accepted 20 July 2009 present a case of lipoblastoma arising in the soft palate, a site that has not been previously reported. By Available online 19 August 2009 doing so, we hope to promote awareness of this pathology and emphasize the importance of using histological and cytogenetic analysis to obtain the correct diagnosis. Keywords: ß 2009 Elsevier Ireland Ltd. All rights reserved. Lipoblastoma Cytogenetics 1. Introduction chromosomal rearrangements target the Pleomorphic adenoma gene-1 (PLAG1) located on chromosome 8q12. The PLAG1 oncogene Lipoblastomas are rare, benign, adipose tumors that are becomes overexpressed by a promoter-swapping event. Two composed of embryonic fat tissue of different maturation stages different genes have been found to fuse with PLAG1 and promote ranging from prelipoblasts to lipoblasts and finally mature the upregulation of the tumor cells: Hyaluronan synthase 2 (HAS2) lipocytes. -
The 2020 WHO Classification of Soft Tissue Tumours: News and Perspectives
PATHOLOGICA 2021;113:70-84; DOI: 10.32074/1591-951X-213 Review The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives Marta Sbaraglia1, Elena Bellan1, Angelo P. Dei Tos1,2 1 Department of Pathology, Azienda Ospedale Università Padova, Padova, Italy; 2 Department of Medicine, University of Padua School of Medicine, Padua, Italy Summary Mesenchymal tumours represent one of the most challenging field of diagnostic pathol- ogy and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis and, as a consequence, of therapeutic options. The recent publica- tion of the new WHO classification of Soft Tissue Tumours and Bone represents a major step toward improved standardization of diagnosis. Importantly, the 2020 WHO classi- fication has been opened to expert clinicians that have further contributed to underline the key value of pathologic diagnosis as a rationale for proper treatment. Several rel- evant advances have been introduced. In the attempt to improve the prediction of clinical behaviour of solitary fibrous tumour, a risk assessment scheme has been implemented. NTRK-rearranged soft tissue tumours are now listed as an “emerging entity” also in con- sideration of the recent therapeutic developments in terms of NTRK inhibition. This deci- sion has been source of a passionate debate regarding the definition of “tumour entity” as well as the consequences of a “pathology agnostic” approach to precision oncology. In consideration of their distinct clinicopathologic features, undifferentiated round cell sarcomas are now kept separate from Ewing sarcoma and subclassified, according to the underlying gene rearrangements, into three main subgroups (CIC, BCLR and not Received: October 14, 2020 ETS fused sarcomas) Importantly, In order to avoid potential confusion, tumour entities Accepted: October 19, 2020 such as gastrointestinal stroma tumours are addressed homogenously across the dif- Published online: November 3, 2020 ferent WHO fascicles. -
2016 Essentials of Dermatopathology Slide Library Handout Book
2016 Essentials of Dermatopathology Slide Library Handout Book April 8-10, 2016 JW Marriott Houston Downtown Houston, TX USA CASE #01 -- SLIDE #01 Diagnosis: Nodular fasciitis Case Summary: 12 year old male with a rapidly growing temple mass. Present for 4 weeks. Nodular fasciitis is a self-limited pseudosarcomatous proliferation that may cause clinical alarm due to its rapid growth. It is most common in young adults but occurs across a wide age range. This lesion is typically 3-5 cm and composed of bland fibroblasts and myofibroblasts without significant cytologic atypia arranged in a loose storiform pattern with areas of extravasated red blood cells. Mitoses may be numerous, but atypical mitotic figures are absent. Nodular fasciitis is a benign process, and recurrence is very rare (1%). Recent work has shown that the MYH9-USP6 gene fusion is present in approximately 90% of cases, and molecular techniques to show USP6 gene rearrangement may be a helpful ancillary tool in difficult cases or on small biopsy samples. Weiss SW, Goldblum JR. Enzinger and Weiss’s Soft Tissue Tumors, 5th edition. Mosby Elsevier. 2008. Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L, Ye Y, Lau AW, Wang X, Oliveira AM. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011 Oct;91(10):1427-33. Amary MF, Ye H, Berisha F, Tirabosco R, Presneau N, Flanagan AM. Detection of USP6 gene rearrangement in nodular fasciitis: an important diagnostic tool. Virchows Arch. 2013 Jul;463(1):97-8. CONTRIBUTED BY KAREN FRITCHIE, MD 1 CASE #02 -- SLIDE #02 Diagnosis: Cellular fibrous histiocytoma Case Summary: 12 year old female with wrist mass. -
Oncology–Solid Tumor
Solid Tumor An overview for school professionals Solid Tumor is an abnormal mass that does not contain cysts or liquid areas. There are several types of solid tumors. They include: Ewing’s Sarcoma, Germ Cell Tumor/Germinoma, Hepatoblastoma, Lipoblastoma, Malignant Fibrous Histiosarcoma, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdomyosarcoma, Synovial Sarcoma, and Wilms Tumor. Common treatment for a solid tumor diagnosis consists of chemotherapy, radiation, and possible surgery. What are some common symptoms of a solid tumor? Pain in specific body part Weight Loss Fatigue Nausea/Vomiting Decreased alertness Decreased ability to attend to tasks What type of support plan is appropriate for a student with a solid tumor? Students with a solid tumor should have a 504 plan/IEP. The diagnosis of a solid tumor gives reasonable cause to bypass the SST process, which will allow you to provide immediate accommodations to the student. All teachers who provide instruction for your student should be made aware of these accommodations. What accommodations are necessary for a student with a solid tumor? ATTENDANCE: Students with a solid tumor frequently miss school. They may require hospitalizations from time to time, sometimes for several weeks. full-time and/or intermittent hospital homebound services suspension of attendance requirements for absences due to medical appointments and illness, including allowances for student to participate in extra-curricular programs and events without penalty due to absences. partial-day attendance, as necessary ASSIGNMENTS: It is important for teacher and parents to ensure that student receive assignments in a timely manner so student does not get further behind. It may also take the student with a solid tumor longer to complete assignments due to fatigue, pain, and/or frequent trips to the restroom. -
Integrated Data Analysis Reveals Uterine Leiomyoma Subtypes with Distinct Driver Pathways and Biomarkers
Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers Miika Mehinea,b, Eevi Kaasinena,b, Hanna-Riikka Heinonena,b, Netta Mäkinena,b, Kati Kämpjärvia,b, Nanna Sarvilinnab,c, Mervi Aavikkoa,b, Anna Vähärautiob, Annukka Pasanend, Ralf Bützowd, Oskari Heikinheimoc, Jari Sjöbergc, Esa Pitkänena,b, Pia Vahteristoa,b, and Lauri A. Aaltonena,b,e,1 aMedicum, Department of Medical and Clinical Genetics, University of Helsinki, Helsinki FIN-00014, Finland; bResearch Programs Unit, Genome-Scale Biology, University of Helsinki, Helsinki FIN-00014, Finland; cDepartment of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki FIN-00029, Finland; dDepartment of Pathology and HUSLAB, Helsinki University Hospital, University of Helsinki, Helsinki FIN-00014, Finland; and eDepartment of Biosciences and Nutrition, Karolinska Institutet, SE-171 77, Stockholm, Sweden Edited by Bert Vogelstein, Johns Hopkins University, Baltimore, MD, and approved December 18, 2015 (received for review September 25, 2015) Uterine leiomyomas are common benign smooth muscle tumors that with deletions affecting collagen, type IV, alpha 5 and collagen, type impose a major burden on women’s health. Recent sequencing studies IV, alpha 6 (COL4A5-COL4A6) may constitute a rare fourth subtype have revealed recurrent and mutually exclusive mutations in leiomyo- (4). HMGA2 and MED12 represent the two most common driver mas, suggesting the involvement of molecularly distinct pathways. In genes and together contribute to 80–90% of all leiomyomas (5). this study, we explored transcriptional differences among leiomyomas Less frequently, leiomyomas harbor 6p21 rearrangements af- harboring different genetic drivers, including high mobility group fecting high mobility group AT-hook 1 (HMGA1) (6).